-
公开(公告)号：US20210307604A1
公开(公告)日：2021-10-07
申请号：US17266973
申请日：2019-08-07
Applicant: Kowa Company, Ltd.
Inventor： Kazunori MATSUMURA , Akio KAWAKAMI
Abstract: The present application discloses an ophthalmic photographing device that enables easy detection of a pupil diameter. The present invention pertains to an ophthalmic photographing device that is provided with: an anterior ocular segment illumination means for illuminating an anterior ocular segment of an eye of a subject with invisible light; an imaging element that is sensitive to at least invisible light and that is for capturing an image of the eye of the subject; and a processing means for processing an image captured by the imaging element, wherein when an image of an index projected onto the anterior ocular segment fulfills a prescribed condition, the processing means starts detection of a pupil diameter of the eye of the subject using an image formed on the imaging element by means of light reflected from the anterior ocular segment that has been illuminated with the invisible light from the anterior ocular segment illumination means.
-
公开(公告)号：US20210290598A1
公开(公告)日：2021-09-23
申请号：US17053223
申请日：2019-05-07
Inventor： Hiroshi ITO , Kazufumi NAKAMURA , Masatoki YOSHIDA , Keisuke INOUE
IPC: A61K31/423 , A61K31/40 , A61K31/405 , A61K31/366 , A61K31/47 , A61K31/22 , A61K31/505 , A61P9/00
Abstract: Provided is a medicament useful for cardiovascular diseases.
An agent for prevention and/or treatment of a cardiovascular diseases, comprising a combination of pemafibrate or a salt thereof and an HMG-CoA reductase inhibitor.-
公开(公告)号：US20210267753A1
公开(公告)日：2021-09-02
申请号：US17274401
申请日：2019-09-09
Applicant: Kowa Company, Ltd.
Inventor： Norio OBA
IPC: A61F2/16
Abstract: An intraocular lens insertion apparatus which allows the intraocular lens to behave more stably. The intraocular lens insertion apparatus includes a substantially tubular apparatus body which has, at a tip end thereof, an insertion tube part for inserting an intraocular lens in a folded state into an eye, the intraocular lens having a lens body and a support, a storage which stores the intraocular lens, and an extruding member which moves the intraocular lens in the insertion tube part by pushing the intraocular lens, and the extruding member has a tip end part having a first protrusion protruding to one side in a left-right direction and a second protrusion protruding to the other side in the left-right direction.
-
公开(公告)号：US11013722B2
公开(公告)日：2021-05-25
申请号：US16272050
申请日：2019-02-11
Applicant: KOWA COMPANY, LTD.
Inventor： Toshiaki Takizawa , Yasunobu Yoshinaka
IPC: A61K31/423 , A61K31/397 , A61K45/06
Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
-
公开(公告)号：US10993799B2
公开(公告)日：2021-05-04
申请号：US15768741
申请日：2016-09-28
Applicant: KOWA COMPANY, LTD.
Inventor： Kenichi Kobayashi , Shuji Abe , Genyo Midorikawa
Abstract: It is provided an intraocular lens insertion system that achieves a preferable insertion of an intraocular lens without using viscoelastic material in an eyeball. The intraocular lens insertion system includes an intraocular lens insertion apparatus configured to use a predetermined driving force to move an intraocular lens and insert the intraocular lens into an eyeball, an irrigating solution infusion apparatus configured to infuse irrigating solution into the eyeball, a driving source configured to deliver the predetermined driving force to the intraocular lens insertion apparatus, an irrigating solution source configured to deliver the irrigating solution to the irrigating solution infusion apparatus, and a switching unit configured to switch in a multistage manner a control of a delivery of the irrigating solution from the irrigating solution source to the irrigating solution infusion apparatus and a control of a delivery of the predetermined driving force from the driving source to the intraocular lens insertion apparatus.
-
Patent Agency Ranking
公开(公告)号：US20210085652A1
公开(公告)日：2021-03-25
申请号：US17095327
申请日：2020-11-11
Applicant: Kowa Company, Ltd.
Inventor： Ryu Oshima , Gary Gordon
IPC: A61K31/423 , A61K9/00 , A61P9/04 , A61P3/10
Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
-
公开(公告)号：US20210077467A1
公开(公告)日：2021-03-18
申请号：US17099167
申请日：2020-11-16
Applicant: Kowa Company, Ltd.
Inventor： Ryu Oshima , Gary Gordon
IPC: A61K31/423 , A61K31/41 , A61K9/00 , A61K31/366 , A61K31/40 , A61K31/47 , A61K31/505 , A61K45/06
Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
-
公开(公告)号：US20210063768A1
公开(公告)日：2021-03-04
申请号：US17096718
申请日：2020-11-12
Applicant: KOWA COMPANY, LTD.
Inventor： Haruo Ishikawa
Abstract: An ophthalmic lens has a cross-sectional shape in an arbitrary meridian direction on a lens surface of the ophthalmic lens. The cross-sectional shape is expressed by the following formula (1), Z = c r 2 1 + [ 1 - c 2 r 2 ( k + 1 ) ] 1 / 2 + A ( θ ) r 2 + B ( θ ) r 4 . In the formula, c is a paraxial curvature of the ophthalmic lens, r is a distance from a lens center of the ophthalmic lens, k is a conic constant of a surface which is in rotation symmetry with respect to an optical axis of the lens in the ophthalmic lens. The variables c, r and k are used in common in the meridian direction on the lens surface, and A(θ) and B(θ) are parameters expressed by functions depending on an angle in the meridian direction.
-
公开(公告)号：US10932663B2
公开(公告)日：2021-03-02
申请号：US16210038
申请日：2018-12-05
Applicant: KOWA COMPANY, LTD.
Inventor： Satoshi Shimada , Takuya Hara
Abstract: In a perimetry to be conducted, designating an inspection region through a region designator, a perimeter is configured to set a required time of the perimetry (upper limit time) through an upper limit condition setter and to determine total number or positions of stimulus presentation spots based upon the upper limit time. In such a configuration, an examinee knows the time to finish the inspection, and is able to highly keep his (her) concentration in comparison with a case where the required time is not known, thereby improving precision of the inspection.
-
公开(公告)号：US20200367743A1
公开(公告)日：2020-11-26
申请号：US16637210
申请日：2018-08-09
Inventor： Norihiko YOKOI , Yuka SUGIURA , Katsumi YABUSAKI
Abstract: A method for dynamically evaluating a tear fluid layer using an interference fringe image of the tear fluid layer composed of a plurality of consecutive frames, and includes: an image creation step of creating at least one break detection image of a first break detection image, a second break detection image, a third break detection image, and a fourth break detection image, which are images for detecting a breaking site of the tear fluid layer; a determination step of determining whether the break detection image created by the image creation step corresponds to a predetermined breakup pattern; a tally step of tallying the determination results determined by the determination step; and an evaluation step of evaluating, on the basis of a tallied result by the tally step, a breakup pattern of the interference fringe image of the tear fluid layer.
-
-
-
-
-
-
-
-
-
Search Results
310
records
(took 0.037 seconds)
